Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health challenge. Despite the availability of antibiotics, the disease continues to pose a significant threat due to the emergence of multi-drug resistant strains. This article aims to provide an overview of the recent advancements and best practices in the management of enteric fever.
Early and accurate diagnosis of enteric fever is crucial for effective management. Advances in molecular diagnostics, such as the introduction of PCR-based assays, have improved sensitivity and specificity. Additionally, rapid diagnostic tests (RDTs) like the Typhidot test have been instrumental in providing timely diagnosis in resource-limited settings.
The emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains of Salmonella has complicated the treatment landscape. However, newer antibiotics such as azithromycin and carbapenems have shown promising results against MDR and XDR strains. Continuous surveillance of antimicrobial resistance patterns is essential to guide empirical therapy.
Vaccination remains a key preventive strategy against enteric fever. The WHO recommends the use of typhoid conjugate vaccines (TCVs) for children over six months in endemic areas. The recent introduction of TCVs, which have a longer duration of protection and greater efficacy, marks a significant advancement in prevention strategies.
An integrated approach to disease surveillance and response is crucial in managing enteric fever. This includes timely reporting of cases, outbreak investigation, and rapid response activities. The use of digital health technologies for real-time surveillance has greatly enhanced this approach.
Best practices in the clinical management of enteric fever include prompt initiation of appropriate antibiotic therapy, supportive care to manage symptoms, and patient education on the importance of completing the antibiotic course. Furthermore, healthcare professionals should advocate for vaccination in high-risk populations and promote good hygiene practices to prevent transmission.
While advancements in diagnostics, treatment, and prevention have improved the management of enteric fever, the emergence of drug-resistant strains remains a significant challenge. It is imperative for healthcare professionals to stay updated on the latest research and guidelines to provide optimal care. The integration of digital health technologies in surveillance and response activities will be instrumental in the fight against this persistent disease.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation